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Clinical research has expanded tremendously in the past few decades and consequently there has been growing 
interest in the ethical guidelines that are being followed for the protection of human subjects. This review summarizes 
historical scandals and social responses chronologically from World War II to the Death of Ellen Roche (2001) to 
emphasize the lessons we must learn from history. International ethical guidelines for studies with human subjects 
are also briefly described in order to understand the circumstances of clinical research. The tasks and responsibilities 
of the institutions and investigators in human subject research to preserve the safety and welfare of research subjects 
are summarized. Next, several debated ethical issues and insights are arranged as controversial topics. This brief 
review and summary seeks to highlight important arguments and make suggestions to institutional review boards 
(IRBs) to contribute to the future evolution of ethics in clinical research as we advance forward. (Korean J Anesthesiol 
2012; 62: 3-12)
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Historical Views on Human Subject Research
Studies on human are imperative for medical progress 
and have expanded our understanding and capability to treat 
serious diseases and entities. However, research with humans 
needs to take into account the ethical dimensions of the reasons 
for running an experiment and the proper procedural steps to 
ensure that the results reflect good science. Protecting human 
participants in research is our top priority and has been given 
great consideration in the ethical conduct of research because 
the exact risks and benefits of research are uncertain. 
“All human beings are born free and equal in dignity and 
rights. They are endowed with reason and conscience and 
should act towards one another in a spirit of brotherhood” 
(Article 1 of the United Nations Universal Declaration of 
Human Rights). These rights have often been ignored in public 
perceptions of human research. Beginning in the seventeenth 
century, the scientific revolution brought about a method 
of investigation using controlled observation and reporting 
of result to the public as proof. The numbers of participants 4 www.ekja.org
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involved in early experiments were small and most often 
included the researchers themselves or their families. The most 
typical and famous example of this was when Edward Jenner 
tested a smallpox vaccine on his son and on the neighborhood 
children in the early modern times. The progression to the 
current status of protecting human research participants has 
been the consequence of historical events in the twentieth 
century. There have been many groundbreaking events 
that have affected the public's perception of human clinical 
research. The history of human subject abuses, scandals, 
tragedies and the responses to them are shown in Fig. 1 in 
chronological order. 
World War II 
In Imperial Japan Army Units 731, 1644, 1855, 8604 (China), 
9420 (Singapore), Japanese doctors conducted live experiments 
with dissection, dismemberment, and bacteria inoculation on 
prisoners of war. They induced epidemics on a large scale, with 
an estimated 3,000 to 200,000 Chinese, Korean, Mongolians, 
and Allied civilians becoming infected [1,2]. Many prisoners 
were killed, directly or indirectly, by these experiments. After 
the war, the Supreme Commander of the Allied Powers in 
Japan, Douglas MacArthur, gave immunity in the name of 
the United States to Shiro Ishii and all members in exchange 
for protecting the results from the Soviet Union. No formal 
investigation or trial took place in association with the Japanese 
experiments. In the meantime, the Nazis were placing victims in 
vacuum chambers with low air pressure and a lack of oxygen in 
order to determine the health effects on pilots at extremely high 
altitudes. Subjects were immersed for hours in tubs of ice water, 
fed nothing but salt water for days, and experimented upon 
Fig. 1. Chronicle of scandals and res-
ponses are presented.5 www.ekja.org
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with techniques for battlefield medicine. At the end of the war, 
23 Nazi doctors and scientists were put on trial in Nuremberg 
from December 9, 1946 to August 20, 1947 for the unethical 
treatment of concentration camp inmates, who were often 
used as research subjects with fatal consequences. Seven were 
sentenced to death. A set of standards known as the Nuremberg 
Code was used for evaluating and judging the defendants.
The nuremberg code and the declaration of Helsinki
The Nuremberg Code comprises such principles as infor-
med consent and absence of coercion; properly articulated 
scientific experimentation; and beneficence towards experi-
ment participants [2]. The code states that: 1) Voluntary 
informed consent is essential without any coercion; 2) Human 
experiments should be designed and based upon prior animal 
experimentation; 3) Expected scientific outcomes should justify 
the experiments; 4) The experiment should be conducted 
only by qualified scientists; 5) The experiment should be 
conducted in a way that avoids all unnecessary physical and 
mental suffering and injury; 6) There should be no expectation 
of death or disabling injury from the experiment. In 1953, the 
World Medical Association (WMA) was provoked to make 
drafts that would apply the Nuremberg Code to the practice 
of human experiment in the medical community. Known 
as the Declaration of Helsinki, it was an expansion upon the 
Nuremberg Code and was first adopted in 1964. It has been 
revised several times (1975, 1983, 1989, 1996, 2000 and most 
recently in 2008) according to the modern ethical theory and 
current clinical and research practice. A prominent point of 
difference from the Nuremberg Code was the flexibility of the 
conditions of consent, which was 'absolutely essential' under 
the Nuremberg code. Research was permitted without consent 
where proxy consent, such as that of a legal guardian, was 
available. The Declaration of Helsinki introduced the concept of 
an independent committee, which evolved into the institutional 
review board (IRB) system used in the US [1]. The Declaration 
of Helsinki focuses on a systematic approach, including 
IRB review, unlike the Nuremberg code, which focused on 
the responsibility of the individual scientist, had no legal 
enforcement and was applied only to non-therapeutic clinical 
research. The Declaration of Helsinki is an important document 
in the history of research ethics as the first significant effort of the 
medical community to regulate research itself. It forms the basis 
of most subsequent documents and is now widely accepted as 
the cornerstone document of human research ethics.
The Beecher article
Dr. Henry K. Beecher, an anesthesiologist, reported 22 
studies describing violations of serious ethical principles in the 
New England Journal of Medicine in 1966 after the publication 
of the Declaration of Helsinki [1,3]. This article sparked a debate 
on research ethics in the US. His examples were not cited 
simply to blame individuals but with the hope that it would call 
attention to abuses, in order to correct them. The experiments 
that Beecher cited demonstrated ethical abuses. Here are two 
examples: number 7 - this study on cyclopropane anesthesia 
and cardiac arrhythmia involved 31 patients. Carbon dioxide 
was injected into the closed respiratory system until cardiac 
arrhythmias appeared. Toxic levels of carbon dioxide were 
achieved and maintained for considerable periods, causing 
various pathologic arrhythmias. Number 17 - live cancer cells 
were intradermally injected without consent into 22 chronically 
ill, debilitated non-cancer patients for a study of immunity 
to cancer (Jewish Chronic Disease Hospital Case, 1963). The 
physicians "did not wish to stir up any unnecessary anxieties in 
the patients" who had "phobia and ignorance" about cancer, so 
they did not tell the subjects that the injection contained cancer 
cells.
The Tuskegee study and the Belmont report
The Tuskegee syphilis study was an infamous clinical 
experiment undertaken by the U.S. Public Health Service, 
which would later become the Centers for Disease Control 
and Prevention (CDC), to study the natural progression 
of untreated syphilis between 1932 and 1972 in Tuskegee, 
Alabama. The study was designed to demonstrate the need 
for establishing syphilis treatment programs by investigating 
the effects of untreated disease. A total of 399 poor, rural black 
men were enrolled, under the impression that they were 
receiving free health care from the U.S. government. Select 
research participants were given free medical care, meals, and 
free burial insurance. However, they were never told they had 
syphilis, nor were they ever treated for disease. In spite of the 
wide use of penicillin as a curative treatment for syphilis by 
1951, treatment continued to be withheld from the research 
subjects. The announcement of the Declaration of Helsinki in 
1964 had no effect on the study. Jean Heller, an Associated Press 
reporter, published a story about the study in the New York 
Times and the Washington Star on July 25, 1972. The public 
reaction was great and Senator Edward Kennedy held hearings 
about these experiments on human subjects. The syphilis study 
was stopped, and treatment was given to the survivors in 1973. 
President Clinton officially apologized to the research subjects 
and their families in 1997. Congress passed a National Act 
in 1974 creating the National Commission for the Protection 
of Human Subjects of Biomedical and Behavioral Research. 
The National Commission published the so-called “Belmont 6 www.ekja.org
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Report” in 1979, which is a landmark of ethical principles in 
human research. The three fundamental ethical principles 
for using any human subjects for research are: 1) Respect for 
persons: protecting the autonomy of all people and treating 
them with courtesy and respect; this is applied in the informed 
consent process. Researchers must be truthful and conduct no 
deception; 2) Beneficence: incorporating the philosophy of "Do 
no harm" while maximizing benefits for the research project 
and minimizing risks to the research subjects is applied through 
risk/benefit assessments; 3) Justice: ensuring reasonable, non-
exploitative, and well-considered procedures are administered 
fairly and equally and applied to the selection of research 
subjects. These principles are comprehensive and are stated to 
understand the ethical issue. The three principles cannot always 
be applied so as to solve beyond dispute particular ethical 
problems, however, and provide an analytical framework 
that will guide the resolution of ethical problems arising 
from research involving human subjects. Today, the Belmont 
Report continues to be an essential reference for institutional 
review boards (IRBs) and remains the basis of human subject 
protection regulations.
Human radiation experiments
Eileen Welsome revealed to the Albuquerque Tribune in 
1993 that researchers injected plutonium into unknown subjects 
to study the effects of the atomic bomb under government 
sponsorship [2]. In 1944, President Clinton formed the Advisory 
Committee on Human Radiation Experiments (ACHRE) to 
investigate human radiation experiments and decide upon 
ethical and scientific standards for evaluating these events. The 
Advisory Committee found that several thousand governments 
had sponsored human radiation experiments, intentionally 
releasing radiation on hundreds of occasions from 1944 to 1974. 
The Nuremberg Code and the Declaration of Helsinki appear to 
have been disregarded during Cold War radiation experiments.
Thalidomide tragedy
Thalidomide was approved in Europe as a sedative drug in 
the late 1950s and sold in a number of countries around the 
world from 1957 until 1961. It was withdrawn from the market 
after being found to have caused birth defects in 10,000 to 
20,000 children. The FDA had not approved the drug but U.S. 
physicians had studied its safety and efficacy. The drugs had 
the side effects of shrinking blood vessels and disrupting the 
normal development of the vessels, affecting development of 
the arms and legs. It was extremely damaging to the fetus if 
taken in the first trimester of pregnancy. In the congressional 
hearing with Senator Hubert Humphrey from 1959 to 1962, it 
was found that many people who were taking the unapproved 
drugs were neither informed that they were being given an 
experimental substance nor asked for their consent. This led 
to the passage of the Drug Amendments sometimes referred 
to as the Kefauver-Harris Amendments. Since the episode with 
thalidomide, researchers have been required to inform subjects 
of a drug's experimental nature and to receive their consent 
before beginning trials. 
The Milgram study
The Milgram experiment (1963) was a series of social psy-
chology experiments conducted by Yale University psychologist 
Stanley Milgram after reading about the Nazi Holocaust. The 
study was intended to measure the willingness of participants' 
obedience to the authorized person who instructed them to 
perform acts that conflicted with their personal conscience. 
Volunteers were recruited for a study of "memory and learning". 
The volunteer was to play role of "teacher" and was required 
to ask the "learner" questions and administer punishment 
via an electric shock when the learner gave wrong answer. 
In reality, there were no electric shocks to the learner, but 
they pretended to receive an electric shock. Two-thirds of the 
volunteers were persuaded by the investigator to administer 
shocks up to the highest level of 450 volts. Upon completion of 
the experiment, the investigator explained the deception. The 
focus of Mailgram’s investigation was the psychological stress 
induced by the experiment upon the volunteers, the deception 
involved and the lack of true informed consent. As a result of 
this controversial study, the conditions of deception in human 
research were limited, and now need careful IRB approval. 
Hepatitis in retarded children 
Experiments were designed to track the development of the 
viral infection of hepatitis and subsequently to test the effects 
of gamma globulin in preventing or ameliorating the disease 
from 1963 through 1966 at the Willowbrook State School, a 
New York State institution for mentally retarded children [4]. 
The subjects, all children, were purposely infected with the 
hepatitis virus; early subjects were fed extracts from the stool 
of infected individuals and later subjects received injections of 
more purified virus preparations. This Hospital did not admit 
new patients after 1964, unless their parents consented to the 
experiment. This case drew public condemnation because of 
the perception that parents and their children were given little 
choice about whether or not to participate in research and for 
performing an experiment on either a normal or a mentally 
retarded child when no benefit can result for the children.7 www.ekja.org
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San Antonio contraceptive study and Tearoom trade 
study
San Antonio contraceptive study: In 1971, an oral contracep-
tive study was conducted on 70 poor Mexican-American 
women to evaluate the efficacy of different kinds of female 
contraceptive pills. A number of indigent Hispanic women, 
who had no way of getting contraceptives, came to a clinic 
seeking contraceptives. They agreed to participate in a study to 
determine the side-effects of contraceptives. The randomized 
half received oral contraceptives and the others a placebo. The 
two halves were switched in the middle of the study. They were 
not informed that they were subjects of this kind of research or 
that they might receive inactive medication. As expected, there 
were high numbers of unplanned pregnancies in the placebo 
group; ten of the 76 participants became pregnant during the 
study.
Tearoom trade study: Anonymous male homosexual en-
coun  ters in public restrooms (a practice that was known as "tea-
rooming" in US gay slang) were studied in a controversial 1970 
Ph.D. dissertation and book titled "Tearoom trade: a study of 
homosexual encounters in public places" by Laud Humphreys. 
Humphreys, as social scientist, acted as a watcher outside 
public toilets where people grouped to engage in anonymous 
homosexual activity. He copied down license plate numbers 
and other identifying information, which he used to get the 
names and addresses of over 100 men who had been involved 
in 50 sex acts (mostly oral sex). He then personally visited their 
homes to interview them about their milieu and family life. 
Many subjects were living with a family in a situation where it 
would be upsetting to disclose their homosexual activity. At no 
time were the subjects informed that they were participating 
in a study about male homosexuality. In his published reports, 
the level of detail was such that the identification of some of his 
subjects was revealed.
Death of Jesse Gelsinger
Jesse Gelsinger, an 18-year-old volunteer, was the first person 
publicly identified as having died in a clinical trial of a gene 
transfer experiment in 1999 [5]. He suffered from ornithine 
trans    carbamylase deficiency, an X-linked genetic disease of the 
liver, the symptoms of which include an inability to metabolize 
ammonia - a byproduct of protein breakdown. He was injected 
with an adenoviral vector carrying a corrected gene to test the 
safety of the procedure and died four days later, despite not 
being sick before the experiment. The principal investigator 
and the University of Pennsylvania shared in a private startup 
company that owned the technology used in the experiment. 
The main issue in this research was conflict of interest (COI). 
Moreover, investigators did not pay attention to animal data 
indicating the possibility of adenovirus-induced liver failure and 
the possible harm to Jesse's already abnormal liver function. 
Investigators did not use the IRB-approved consent form 
and had reported instances of mild liver toxicity in previous 
participants as adverse events.
Death of Ellen Roche 
Ellen Roche, a healthy 24-year-old volunteer in an asthma 
study, died in 2001 because she inhaled hexamethonium, a 
medication used for treating high blood pressure in the 1950s 
and 60s [5]. She developed a cough and her condition worsened 
over the next week until she was put on a ventilator with 
progressive multi-organ failure. She was a technician from the 
Johns Hopkins Asthma and Allergy Center who volunteered to 
participate in a study designed to provoke a mild asthma attack 
in order to help doctors discover the reflex that protects the 
lungs of healthy people against asthma attacks. She died about 
a month after taking part in the study. Although both a National 
Institute of Health (NIH) and the IRB had approved the study, 
hexamethonium was not approved as medication by the Food 
and Drug Administration (FDA). A federal investigation found 
serious problem with IRB reviews at the University and accused 
the IRB of failing to take proper precautions. The IRB did not 
follow federal regulations and all federally funded research 
was suspended. Other universities were shocked and began to 
strengthen their IRB committees. The public expressed outrage 
at this case, which was readily understandable. The culture 
of possibly putting coercive pressure on Asthma and Allergy 
Center employees to participate was pointed out as a grave 
mistake. 
International Ethical Guidelines for Human 
Subjects
The Council for International Organizations of Medical 
Sciences (CIOMS) in Collaboration with the World 
Health Organization (WHO) guidelines
The CIOMS (http://www.cioms.ch/) is an international, 
non-government, not-for-profit organization established jointly 
by WHO and UNESCO in 1949 to serve the scientific interests 
of the general international biomedical community, and has 
been active in dispersing guidelines for the ethical conduct of 
research. The international ethics guidelines created in 1993 by 
CIOMS and updated in 2002 for biomedical research including 
human subjects were intended to guide investigators from more 
technically advanced countries when conducting research 
in developing countries. The guidelines were intended to 8 www.ekja.org
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supplement alleged omissions from the Nuremberg Code and 
the Declaration of Helsinki, particularly when applied to cross-
cultural study. The CIOMS guidelines take into account cultural 
differences in ethical standards. The CIOMS 21 guidelines (15 in 
the original report) address issues including informed consent, 
standards for external review, recruitment of participants, and 
more. The guidelines are general instructions and principles of 
ethical biomedical research, and have been revised to account 
for the latest ideas and practices, such as the Declaration of 
Helsinki. 
The International Conference on Harmonization- 
Good Clinical Practice (ICH-GCP) guidelines 
The ICH (http://www.ich.org/) is composed of expert 
working groups from the pharmaceutical industry and 
regulatory authorities in the European Union, Japan and the 
United States, as well as those of Australia, Canada, the Nordic 
countries and the World Health Organization (WHO). The 
goal is to discuss the scientific and technical aspects of drug 
registration and published guidelines for GCP in response 
to the increasingly global face of drug development, so that 
the benefits of international harmonization for better global 
health can be realized worldwide. The objective of the ICH-
GCP (Geneva: 1996) guidelines is to provide a unified standard 
for the European Union (EU), Japan and the United States 
to facilitate the mutual acceptance of clinical data by the 
regulatory authorities. Thus, any country that adopts this 
guideline technically follows this same standard. Clinical studies 
should be carried out according to International Conference on 
Harmonization (ICH)/WHO Good Clinical Practice standards. 
This worldwide GCP document offers standardization for 
clinical trials of drugs. Standards for the design, conducting, 
analyzing, monitoring, auditing, recording, and reporting of 
clinical trials provide assurance that the data and reported 
results are credible and accurate, and that the rights, integrity, 
and confidentiality of trial subjects are protected. Ethical 
and scientific quality standards for designing, conducting, 
recording and reporting trials that involve the participation of 
human subjects ensure that the rights, safety and well-being 
of the trial subjects are protected. GCPs are consistent with the 
ethical principles originated in the Declaration of Helsinki. The 
ICH topics are divided into four categories (Q: quality topics, 
S: safety topics, E: efficacy topics E6 (R1: Revision 1) - Good 
Clinical practice, M: multidisciplinary topics) and ICH topic 
codes are assigned according to these categories. The ICH-GCP 
includes the following sections: (Section 1): Glossary, (Section 
2): The Principles of ICH-GCP, (Section 3): Institutional Review 
Board/Independent Ethics Committee (IRB/IEC), (Section 
4): Investigator, (Section 5): Sponsor, (Section 6): Clinical Trial 
Protocol and Protocol Amendments, (Section 7): Investigator's 
Brochure, (Section 8): Essential Documents for the Conduct of 
a Clinical Trial. ICH-GCP, therefore, embraces all aspects of all 
clinical trials. KGCP (January 1, 2000) was completely revised to 
harmonize with ICH-GCP regarding standards for clinical trials 
of drugs in Korea; compliance with KGCP during clinical trials 
is inspected for all investigations. 
Task and Responsibilities in Human Subject 
Research
Institution 
The Institution has the responsibility to comply with 
the laws and guidelines regarding oversight of all human 
research activities, especially when the research involves 
vulnerable people [6]. It also has the responsibility of educating 
investigators on ethical issues, scientific truthfulness, 
preventing misconduct and conflicts of interest. The institutions 
are required to have 1) ethical (IRB) review of protocol and 
informed consent, 2) administrative review of proposals, 
contract and grants, 3) scientific peer review [6].
Ethical review: By compliance with the law and guidelines, 
the institution can guard the rights, safety and welfare of 
research participants. The IRB must review the following 
requirements in order to give approval to research: 1) the 
risks are rational and minimized in relation to the anticipated 
benefits to the subjects based on a risk/benefit analysis; 2) 
the choice of subjects is equitable; 3) informed consent is 
obtained from each potential subject or a legally responsible 
representative unless waived in harmony with the law and 
guidelines. This should be documented on the consent form; 4) 
when subjects are likely to be vulnerable to coercion or undue 
influence, additional safeguards are needed; 5) appropriate 
monitoring and observation with continuing review should 
be scheduled when collecting data to ensure the safety of the 
subjects, protect the privacy of participants and to maintain the 
confidentiality of data. The purpose of the IRB is to ensure that 
the investigator complies with the protocol and to demonstrate 
that the trial is necessary and that the risk-benefit ratio is 
acceptable by reviewing key trial documents to ensure that the 
subjects’ rights and well-being are protected. 
Administrative review: the research institution generally 
ensures that proposals and allied budgets are in compliance 
with the law and institutional policy including IRB review 
where suitable. If the researcher has a conflict of interest, 
the institution should make a decision as to whether the 
conflict can be managed. The research institution has usually 
established a Conflict of Interest (COI) committee to avoid 
and/or to minimize potential conflicts under the instruction of 9 www.ekja.org
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institutional policy. 
Scientific peer review: scientific review should examine the 
soundness and worth of the hypothesis, the procedure to prove 
the hypothesis and the appropriateness of the methods to be 
used. It is unethical to expose subjects to unnecessary risks 
and sample size justifications must be back up based on the 
expected results and statistical significance. When the IRB plays 
the dual role of conducting the scientific review, scientifically 
qualified experts must be added to the IRB, or the IRB should 
establish a subcommittee for supporting scientific review. 
ICH-GCPs provide protection for human volunteers and 
ensure the accuracy and reliability of data generated in the 
course of clinical trials. Compliance with these standards is a 
public pledge that the rights, safety and well-being of clinical 
trial participants will be protected. GCPs cover obtaining 
informed consent, documentation, reporting adverse events 
and proper record keeping.
Investigator
The welfare and safety of research subjects is ultimately the 
responsibility of the investigator. The researcher thus shares 
responsibility with the research institution and sponsors. 
Investigators must be properly qualified to conduct the research 
and studies must be suitably designed to produce valid results. 
Investigators are responsible for ensuring that research is 
conducted according to the research design as approved by 
the IRB [4,6]. Good and professional judgment is required 
throughout the research process to guarantee the protection 
of study subjects. Investigators must protect and respect the 
personal dignity and autonomy of the research volunteers 
by obtaining informed consent before a person agrees to 
participate in a study. Subjects are protected from harm 
by study proposals that maximize anticipated benefits and 
minimize possible risks. The benefits and burdens of research 
are reasonably distributed. Protecting subjects and achieving 
scientific progress are not exclusive and not conflicting. 
The principal investigator can delegate study-specific task 
and responsibility to other team members including sub-
investigators, the Clinical Research Coordinator (CRC), as well 
as a variety of professionals, statistician, laboratory technicians 
and administrative staff. Studies should be conducted according 
to the protocol (study design) that the IRB approved. This is 
the duty of an investigator in amenability with the regulations. 
The protocol is a formally written document detailing how 
the research is to be conducted. The institution policies, 
guidelines and law state the items that must be included in 
the protocol and informed consent. The study procedures and 
inclusion/exclusion criteria are to be evaluated and checked 
while the protocol is in its draft form. The investigator ought 
to decide upon the feasibility of recruiting volunteers with/
without advertising prior to approving a study. All changes to 
the protocol must be agreed upon by the IRB and sponsors 
before execution. Investigators should document and clarify 
deviances from the protocol. The detection of major or repeated 
noncompliance with the protocol can result in closing of the 
study or even ineligibility as an investigator. 
Ethical Issues
Ethics in clinical design 
Researchers and IRB members must carefully inspect and 
bear in mind the details of research design protocol such as 
randomization, blinding, and the problem of placebos as 
controls and assessment of risks and benefits.
The distinction between research and treatment
The ethics of research and therapy are fundamentally 
different. However, clinical research and therapy both 
provide medical care and are performed by physicians with 
similar interventions of treatment in the clinical setting [2]. 
Experimental interventions and the best proven therapy should 
appear equally effective. Physicians commonly conduct clinical 
research and medical therapy as intimately connected. The 
purpose of clinical medicine is to provide optimal medical care 
for individual patients; it is ethically governed by the principle 
of therapeutic beneficence and nonmaleficence. On the other 
hand, clinical research is not a therapeutic activity devoted 
to the personal care of patients. It is carried out to answer a 
scientific question with the aim of producing knowledge that 
can be generalized and applied to future patients. The clear 
demarcation between research and therapy becomes blurred 
when physician-investigators view patients as subjects in 
practice. Physicians and patients commonly fail to appreciate 
the distinction between research and therapy because of the 
similarity in the physician and patient relationship, especially 
with regard to the setting out of innovative or non-validated 
therapies. To be sure, the risks need to be assessed by physicians 
and patients and they must weigh carefully the options of 
standard treatment and research intervention, of course with 
the informed consent of the patient.
Clinical equipoise and randomized clinical trials (RCTs)
RCT is a study design that randomizes whether the 
participants are given treatment or placebo for the sake of 
eliminating prejudice. RCTs are ethical only in conditions 
of "clinical equipoise" being assured. Random selection of 
participation can yield scientifically convincing data for use 
in future patients. However, critics of RCTs say that individual 10 www.ekja.org
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therapy is determined not by the participants' physical needs 
and personal value but by the statistical requirements of the 
study design. Randomization to get data for future patients 
sacrifices benefits for the present patients. RCTs violate the 
physician's duty of giving the most appropriate treatment to 
their patients. One way of solving this problem is to obtain fully 
informed consents of the participants. Small losses in some 
patients might be ethically tolerated as long as the patients are 
not exposed to unnecessary risk. RCTs are ethically permissible 
using a standard of clinical equipoise in the context of non-life 
threatening therapies. Serious problems remain, however, in 
clinical equipoise that can easily be upset. So long as the study 
intervention is balanced, RCTs are acceptable. 
Placebos in clinical research
RCTs are well recognized as the most desirable type of 
study to evaluate a new treatment, but many clinical trials 
are concerned about the use of placebos as controls. Placebo 
controls are intended to ascertain the authentic effectiveness 
of a treatment while eliminating various disturbing factors 
and to determine the actual therapeutic efficacy of a new 
treatment. If researchers wish to test a new treatment in the 
absence of a known effective treatment, the use of a placebo 
is usually problematic and unethical. Comparisons of new 
drugs to current standard medications and comparisons to 
placebos are different. The latter comparison conflicts with the 
Declaration of Helsinki, which requires that any new method 
be tested against the best existing prophylactic, diagnostic, and 
therapeutic method(s). Placebos can have their own powerful 
ambiguous effects. Comparing against placebos is not the 
same thing as testing against nothing. A lack of difference 
between a new drug treatment and the standard treatment 
does not necessarily mean that the new drug is effective. The 
new drug and the standard treatment could both be effective 
or both be ineffective. The standard treatment might be 
generally effective, but lose its effect in a particular situation. 
The FDA considers placebo controls to be the gold standard 
of measuring diagnostic or therapeutic efficacy because they 
rely on statistical significance in judging the efficacy of the new 
drug. It is likely that placebo studies will continue to be used. 
However, they should be used with caution so that patients do 
not face unnecessary pain or disease on account of a medical 
experiment in keeping with the ethical use of placebos in any 
experiment. 
The ethics of phase I research
The main purpose of Phase I trials is to determine the 
highest tolerated dose of a new drug in humans, with the hope 
of gathering information that may help patients in the future. 
Human studies, especially phase I cancer trials, bring about 
much tension and conflict between the goals of science and 
those of clinical care, bringing special challenges to IRB review. 
Almost all Phase I studies are executed on normal human 
volunteers to determine the level of toxicity and pharmacologic 
effects of receiving higher doses of a drug on a small number 
of participants. However, studies that are conducted on sick 
patients, such as trials of cancer drugs, can be extremely 
controversial because the drugs are too toxic to be administered 
to a healthy volunteer. This category of patients is seriously 
ill and highly vulnerable. These individuals are designated to 
participate in phase I oncology trials for the good of society 
with no premeditated benefits and need special protection. 
Sometimes they are under the misconception that the trials 
are designed to help them [5]. Consent documents should 
detail the purpose of this trial and indicate that the dose will 
be increased until the patient gets extremely sick. Moreover, 
it is impossible to predict the side effects that the patient will 
experience because the study is designed to push the dose of 
the study drug until toxicity is unacceptable. Despite this, most 
participants think that the main purpose of trial is to make them 
better. Information including the purpose, risks and benefits 
of the study should be provided to make clear the distinction 
between research and patient care. Standardized wording 
should be required on these consent documents. 
Participant recruitment
Clinical trials should be conducted with the willingness 
and generosity of those who serve as human participants. 
Recruitment is almost inevitably time-consuming, expensive, 
and requiring of the investigator's realistic determination of 
its feasibility prior to performing the trials. Many patients still 
have the idea that clinical trials are treatment, especially when 
they have serious disease. Investigators should guard against 
exaggerating the benefits of research and should ensure realistic 
assessments of the benefits and risks before volunteering their 
patients to become subjects. Concerns prior to participation 
are the fear of receiving a placebo instead of the active drug, as 
well as the risky side effects. The fact that research participants 
are supererogatory volunteers means that investigators and 
physicians should sustain heavy responsibilities not to violate 
their trust. People should be selected to make sure that the 
burdens and potential benefits are equitably dispersed. It is 
ethically justified to exclude those at greater risk of injury. 
Therefore, after careful selection of subjects best able to answer 
the scientific questions and to understand the risks and 
potential benefits posed by that particular trial, participants 
are identified, recruited and enrolled according to their 
eligibility criteria. The scientific and ethical basis of including 
women and minorities in clinical research are that many have 11 www.ekja.org
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begun to see access to clinical research and to test drugs as an 
advantage rather than a burden from which people should be 
protected. Some even saw their participation in the research as 
not only beneficial, but as essential to their medical care and 
their chance of survival. On the other hand, once recruitment 
and enrollment of participants with appropriate inclusion 
and exclusion criteria have been decided, one controversial 
problem is the amount of money to pay. Payment should 
be prohibited, although compensation for expenses may be 
ethically permitted. 
Informed consent 
The voluntary consent of the participant in a clinical trial 
is now an indispensible part of human research. The process 
need to include the three key components of information, 
understanding and voluntary agreement, in order to be 
ethically suitable. The firmest foundations for the requirement 
to seek consent are based upon the ethical principle of respect 
of persons described in the Belmont Report. These imply 
that individuals should be treated as self-ruling agents and 
that person with diminished autonomy should be protected. 
Participating subjects will be treated as an end and not 
merely as a means to another's end, based on Kantian terms. 
However, informing the prospective subject that a clinical trial 
will be at least in part a means is a consent issue in human 
research that differs from practice. Only emergency and 
therapeutic concession exceptions are allowed in the context 
of medical practice. In cases of emergency or life-threatening 
situations, informed consent can be impossible to get and can 
sometimes cause postponement of asking the consent of the 
subject or permission. There is continued controversy over 
deferred consent as privileges [7]. The therapeutic exception to 
withholding information is when disclosure would be harmful 
to the patient's interest or well-being. The subject might be 
invited to consent to incomplete disclosure with the promise of 
full disclosure at the termination of the research. Fully informed 
consent is an ideal goal that we can never achieve, but we must 
attempt to reach it. Competence and comprehension to reach 
an enlightened decision is the domain of controversy. Many 
studies involve unreal or uncertain benefits and the subject's 
participant represents only a societal good. We need to provide 
subjects the opportunity to choose what is best for themselves 
in order to gain their trust while also taking into account the 
ethical issues of consent.
International research 
A vital issue in international research is exploitation in 
developing countries. In most developing countries, obtaining 
voluntary and informed consent is problematic, making it 
difficult to conduct studies [8]. Many trials that make use of 
impoverished populations in developing countries violate the 
most fundamental understanding of ethical attitudes. However, 
researchers insist that doing research with placebo-controlled 
studies in developing countries is at least equivalent to the 
standard of care in these countries, which consists of unverified 
regimens or no treatment at all. It is now ethically acceptable 
to most that researchers working in developing country have 
a responsibility to provide treatment that conforms to the 
standard of care in the sponsoring country, and, when possible, 
to resolve the double standard between developing and 
developed countries. Cultural relativism or community beliefs 
cannot be used as a justification for violating universal human 
rights. There must be a core list of human rights that must be 
protected despite local distinctions in their superficial features. 
Ethical standards in medicine similarly cannot be relative. The 
force of local customs or law cannot justify abuses of certain 
fundamental rights, and the right of self-determination based 
on informed consent. When researchers from developed 
countries collaborate on studies performed in developing 
countries, it is important to stick to these fundamental prin-
ciples to avoid ethical imperialism and to justify studies. There 
is an enormous amount of research to be done in developing 
countries, with their diverse and large populations and the 
burden of public healthcare that has yet to be solved. A truly 
international effort is needed to relieve the populations that 
have suffered so dreadfully. A collaborative effort will be 
required to conduct ethically and scientifically sound research 
that yields solid results. 
Other issues
Remaining issues include special populations, genetics 
research, stored human biological specimens, human embryos 
and stem cells, drug challenges and drug washout studies, 
research with communities, scientific misconduct, behavior 
of clinical investigators, conflicts of interest, research with 
secondary subjects, tissue studies and records review, and 
behavioral research issues [4]. These issues are not presented 
here due to lack of space, but need to be debated. They have not 
been excluded here because they are any less important than 
those discussed above. 
Criticisms to the IRB System and Suggestions
IRB review is the main body of research supervision, making 
IRBs the key protectors of human research participants. 
However, concerns have been raised about the adequacy of 
IRB review. In spite of the roles and responsibilities of IRBs, 12 www.ekja.org
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the fact is that many are overloaded, understaffed and faced 
with a variety of skeptical criticism. Many IRBs are lacking 
the resources and staff to carry out the hefty task of reviewing 
research [9,10]. 
IRBs have acknowledged a number of criticisms for their 
performance: 1) the monitoring function of IRBs ongoing 
research is not fulfilled on their role for annual review, consent, 
adherence to protocol, and data integrity. Auditing and 
quality assurance programs serve an important preventive 
role; 2) both free standing commercial review boards (non-
institutional review boards), which are financially dependent 
on their client, and academic IRBs, the members of which are 
inclined to accept the studies of their colleagues, have conflicts 
of interest inherent in their structure. The independence and 
integrity of both types of IRBs should be secured to avoid 
problems; 3) multi-center trials by different IRBs cause delays 
and inconsistencies in IRB review. Exempted or expedited 
review at another site might be considered to eliminate 
duplication of effort and to reduce workload when the same 
study is fully reviewed at some local IRB. The central IRB model 
with facilitated review process could be a reasonable way to 
lessen the burden on local IRBs; 4) IRBs pay out too much 
time reviewing and revising consent forms. Usually consent 
forms are written at the reading level of a college graduate, and 
different IRBs in multi-center trials may produce inconsistent 
consent forms; 5) a review of the scientific benefits of the trial is 
often beyond the scope of the IRB. 
Accreditation of IRBs may be an effective approach to 
improving quality, as an indicator of superiority in human 
subject protection. The Association for the Accreditation of 
Human Research Protection Programs (AAHRPP) carries out 
voluntary accreditation of IRBs requiring self-assessment, 
site visits, and evaluation. Electronic and structured forms are 
also suggested to reduce paper work and expedite the review 
process.
Conclusions 
Biomedical research has made remarkable advances over 
the past century; as a result, ethics in clinical research is of more 
concern than ever before. There was little public dispute over 
the ethics of biomedical research until the 1960s, when scandals 
appeared to erupt worldwide and were opened to the public 
(Fig. 1). There have been many responses to these scandals 
including recognition of the need for standards and guidelines 
in the ethics of clinical research. The growing necessity for ethics 
in clinical research has raised concerns related to controversial 
issues in the processing of the formal mechanism known as 
the IRB. There exist various perspectives in special topics with 
or without consensus. This paper first introduces historically 
evoked scandals and responses, and then identifies key ethical 
issues and insights, with topics limited by space constraint. 
Selected debates are intended as a guide to the ethical issues 
confronted by physicians and researchers. Research ethics is an 
essential part of good research practice to protect participants in 
clinical studies. It is our optimistic belief that these challenging 
issues will be resolved through a consensus in the future. It is 
also my hope that this review provides an idea of the ethical 
framework to those investigators and anesthesiologists who will 
need to meet the challenges of changing patterns of research 
circumstances.
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